| |
| |
| |
Centre for Policy on Ageing | |
 | |
|
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older
— implications for the use of antiresorptive agents in the old and oldest old | | Author(s) | Steven Boonen, Michael R McClung, Richard Eastell |
| Journal title | Journal of the American Geriatrics Society, vol 52, no 11, November 2004 |
| Pages | pp 1832-1839 |
| Source | http://www.americangeriatrics.org http://www.blackwellpublishing.com |
| Keywords | Older women ; Drugs ; Osteoporosis ; Fractures ; Clinical surveys ; Longitudinal surveys ; United States of America. |
| Annotation | Analysis is based on combined data from three randomised, double-blind, controlled 3-year fracture endpoint trials conducted from November 1993 to April 1998: the Hip Intervention Program (HIP), Vertebral Efficacy with Risedronate Therapy - Multinational (VERT-MN), and VERT North America. Patients received placebo (n=688) or risedronate 5 mg/d (n=704) for up to 3 years. All patients received 1,000 mg/d calcium and, if baseline levels were low, up to 50 IU/d vitamin D. After 1 year, the risk of new vertebral fractures in the risedronate group were 81% lower than with placebo. The number of women who needed to be treated to prevent one new vertebral fracture after 1 year was 12. This early onset of efficacy was consistent across the clinical programmes, and anti-fracture efficacy was confirmed after 3 years. These findings provide the first evidence that, even in the very old, reducing bone resorption rate remains an effective treatment strategy for osteoporosis. Because each therapeutic agent used in the treatment of osteoporosis may have unique characteristics, the observations made in this study should not be assumed to apply to other biophosphonates. (RH). |
| Accession Number | CPA-050215202 A |
| Classmark | BD: LLD: CLO: CUF: 3G: 3J: 7T |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|
|